Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Harmony Biosciences Holdings, Inc.HRMY · Entity 4381 | Director · PRESIDENT, CEO | August 15, 2022 | August 16, 2022 |
| NOVAVAX INCNVAX · Entity 4632 | Director · President and CEO | March 02, 2026 | March 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Harmony Biosciences Holdings, Inc.
Report date August 15, 2022 · Filed August 16, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-08-15 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-08-15 · Exercise / conversion · Acquired 40,000 · Balance 40,000 Row 2 · 2022-08-15 · Sale · Disposed 39,091 · Balance 909 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.56 to $51.54. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-08-15 · Sale · Disposed 909 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.56 to $52.05. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $8.22 · Expires 2027-10-02 | Direct | 114,751 |
Reported balance
After 2022-08-15 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2022-08-15 · Exercise / conversion · Disposed 40,000 · Balance 114,751 F4: The stock option vests in five equal annual installments beginning on October 1, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $50.56 to $51.54. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $51.56 to $52.05. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The stock option vests in five equal annual installments beginning on October 1, 2018.
NOVAVAX INC
Report date March 02, 2026 · Filed March 09, 2026 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Statutory Stock Option NQSEC Table II · derivative / convertible security · Conversion / exercise price $10.11 · Expires 2036-03-02 | Direct | 551,500 |
Reported balance
After 2026-03-02 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2026-03-02 · Grant · Acquired 551,500 · Balance 551,500 F1: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing. F2: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4/A has been filed solely to amend the exercise price as originally reported in Column 2 and price of derivative security as originally reported in Column 8 of Table II of the Reporting Person's Form 4 filed on March 3, 2026. All other information remains unchanged from the March 3, 2026 filing.
F2: One quarter (1/4) of the shares subject to this option granted under the Plan vest on the first anniversary of March 2, 2026, and the remaining three-quarters (3/4) of the shares vest in equal monthly installments over the following three (3) years, in each case subject to continued employment with the Company through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 03, 2022 Filed Jan 5, 2022 21:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 10,647 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-22-001475 · tm221863-1_4seq1.xml · derivative · entry 5 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 252,804 Underlying: Common Stock · 10,647 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 251,801 shares, and will vest with respect to the remainder of the shares on October 1, 2022. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 10,647 | $45.17 | $480,935.64 |
DisclosureSEC source: 0001104659-22-001475 · tm221863-1_4seq1.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.37. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 21:15 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 10,647 | $8.22 | $87,518.34 |
DisclosureSEC source: 0001104659-22-001475 · tm221863-1_4seq1.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,647 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:18 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 1,300 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-21-154289 · tm2135185-4_4seq1.xml · derivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 263,451 Underlying: Common Stock · 1,300 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is currently vested with respect to 251,801 shares, and will vest with respect to the remainder of the shares on October 1, 2022. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:18 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 1,300 | $45.03 | $58,538.48 |
DisclosureSEC source: 0001104659-21-154289 · tm2135185-4_4seq1.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.15. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 27, 2021 Filed Dec 29, 2021 21:18 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 1,300 | $8.22 | $10,686.00 |
DisclosureSEC source: 0001104659-21-154289 · tm2135185-4_4seq1.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,300 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 01:22 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0001104659-21-150129 · tm2135185-2_4seq1.xml · derivative · entry 4 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,751 Underlying: Common Stock · 25,000 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: The stock option is currently vested with respect to 251,801 shares, and will vest with respect to the remainder of the shares on October 1, 2022. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 01:22 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 11,860 | $38.43 | $455,779.80 |
DisclosureSEC source: 0001104659-21-150129 · tm2135185-2_4seq1.xml · nonDerivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.20 to $38.69. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 01:22 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 13,140 | $38.02 | $499,628.79 |
DisclosureSEC source: 0001104659-21-150129 · tm2135185-2_4seq1.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,860 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.20 to $38.19. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 13, 2021 Filed Dec 16, 2021 01:22 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 25,000 | $8.22 | $205,500.00 |
DisclosureSEC source: 0001104659-21-150129 · tm2135185-2_4seq1.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 22:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionStock Option · Derivative | 25,000 | $0.00 Strike: $8.22 | $0.00 |
DisclosureSEC source: 0000899243-21-035891 · doc4.xml · derivative · entry 3 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,751 Underlying: Common Stock · 25,000 shares Expires 2027-10-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The stock option is currently vested with respect to 188,851 shares, and will vest with respect to the remainder of the shares in two equal annual installments beginning on October 1, 2021. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 22:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | SaleCommon Stock | 25,000 | $35.93 | $898,262.50 |
DisclosureSEC source: 0000899243-21-035891 · doc4.xml · nonDerivative · entry 2 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.45 to $36.38. The reporting person undertakes to provide the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 13, 2021 Filed Sep 14, 2021 22:45 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | Exercise / conversionCommon Stock | 25,000 | $8.22 | $205,500.00 |
DisclosureSEC source: 0000899243-21-035891 · doc4.xml · nonDerivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 18, 2020 Filed Aug 21, 2020 00:13 UTC | Harmony Biosciences Holdings, Inc. HRMY · Entity 4381 | GrantStock Option · Derivative | 144,856 | $0.00 Strike: $24.00 | $0.00 |
DisclosureSEC source: 0000899243-20-023136 · doc4.xml · derivative · entry 1 Jacobs John C · CIK 0001820836 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,856 Underlying: Common Stock · 144,856 shares Expires 2030-08-18 F1 · derivative.exercise_date: The stock option shall vest in five equal annual installments beginning on August 21, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.